



February 26, 2016

## Vericel to Host Fourth-Quarter 2015 Earnings Webcast and Conference Call on March 14, 2016

CAMBRIDGE, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:

**What:** Vericel Corporation Fourth-Quarter 2015 Earnings Call

**When:** Monday, March 14, 2016 at 8:00am (EDT)

**Where:** <http://investors.vcel.com/events.cfm>

**How:** The conference call will be available live in the Investors section of the Vericel website at <http://investors.vcel.com/events.cfm>. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.

To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2015 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237- 1173.

If you are unable to participate in the live call, the webcast will be available at <http://investors.vcel.com/events.cfm> until March 14, 2017. A replay of the call will also be available until 11:59 pm (EDT) on March 18, 2016 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 55599059.

### About Vericel Corporation

Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel<sup>®</sup> (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel<sup>®</sup> (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI<sup>™</sup>, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel<sup>®</sup> and Carticel<sup>®</sup> are registered trademarks and MACI<sup>™</sup> is a trademark of Vericel Corporation. © 2016 Vericel Corporation. All rights reserved.

### CONTACT:

Chad Rubin  
The Trout Group  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
(646) 378-2947

or

Lee Stern  
The Trout Group  
[lstern@troutgroup.com](mailto:lstern@troutgroup.com)  
(646) 378-2922